Novavax Inc (NVAX): EPS (Diluted)
$2.58
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.58 | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$1.23 | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$5.41 | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$8.42 | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$23.44 | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$7.27 | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$5.51 | n/a | 2022-03-01, From 2019-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Novavax Inc (NVAX) | 2025-12-31 | $2.58 | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.16 | +152.2% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.56 | -25.4% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.21 | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $0.86 | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$7.26 | n/m |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.94 | +424.3% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.78 | +58.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $0.60 | -25.9% |
Compare NVAX, TECH, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗